The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice - PubMed (original) (raw)
Affiliations
- PMID: 16380483
The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice
Shanqin Xu et al. Diabetes. 2006 Jan.
Abstract
Arachidonic acid metabolites, some of which may activate thromboxane A(2) receptors (TPr) and contribute to the development of diabetes complications, including nephropathy, are elevated in diabetes. This study determined the effect of blocking TPr with S18886 or inhibiting cyclooxygenase with aspirin on oxidative stress and the early stages of nephropathy in streptozotocin-induced diabetic apolipoprotein E(-/-) mice. Diabetic mice were treated with S18886 (5 mg . kg(-1) . day(-1)) or aspirin (30 mg . kg(-1) . day(-1)) for 6 weeks. Neither S18886 nor aspirin affected hyperglycemia or hypercholesterolemia. There was intense immunohistochemical staining for nitrotyrosine in diabetic mouse kidney. In addition, a decrease in manganese superoxide dismutase (MnSOD) activity was associated with an increase in MnSOD tyrosine-34 nitration. Tyrosine nitration was significantly reduced by S18886 but not by aspirin. Staining for the NADPH oxidase subunit p47(phox), inducible nitric oxide synthase, and 12-lipoxygenase was increased in diabetic mouse kidney, as were urine levels of 12-hydroxyeicosatetraenoic acid and 8-iso-prostaglandin F(2alpha). S18886 attenuated all of these markers of oxidant stress and inflammation. Furthermore, S18886 significantly attenuated microalbuminuria in diabetic mice and ameliorated histological evidence of diabetic nephropathy, including transforming growth factor-beta and extracellular matrix expression. Thus, in contrast to inhibiting cyclooxygenase, blockade of TPr may have therapeutic potential in diabetic nephropathy, in part by attenuating oxidative stress.
Similar articles
- The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus.
Zuccollo A, Shi C, Mastroianni R, Maitland-Toolan KA, Weisbrod RM, Zang M, Xu S, Jiang B, Oliver-Krasinski JM, Cayatte AJ, Corda S, Lavielle G, Verbeuren TJ, Cohen RA. Zuccollo A, et al. Circulation. 2005 Nov 8;112(19):3001-8. doi: 10.1161/CIRCULATIONAHA.105.581892. Epub 2005 Oct 31. Circulation. 2005. PMID: 16260636 - Renal effects of S18886 (Terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes.
Sebeková K, Eifert T, Klassen A, Heidland A, Amann K. Sebeková K, et al. Diabetes. 2007 Apr;56(4):968-74. doi: 10.2337/db06-1136. Epub 2007 Jan 31. Diabetes. 2007. PMID: 17267764 - Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS.
Ding H, Hashem M, Triggle C. Ding H, et al. Eur J Pharmacol. 2007 Apr 30;561(1-3):121-8. doi: 10.1016/j.ejphar.2006.12.034. Epub 2007 Jan 20. Eur J Pharmacol. 2007. PMID: 17292348 - Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban).
van der Hoorn JW, Jukema JW, Bekkers ME, Princen HM, Corda S, Emeis JJ, Steendijk P. van der Hoorn JW, et al. Crit Care Med. 2008 Sep;36(9):2576-82. doi: 10.1097/CCM.0b013e318183f0fd. Crit Care Med. 2008. PMID: 18679128 - TP receptors and oxidative stress hand in hand from endothelial dysfunction to atherosclerosis.
Félétou M, Cohen RA, Vanhoutte PM, Verbeuren TJ. Félétou M, et al. Adv Pharmacol. 2010;60:85-106. doi: 10.1016/B978-0-12-385061-4.00004-0. Adv Pharmacol. 2010. PMID: 21081216 Free PMC article. Review.
Cited by
- Molecular insights and therapeutic targets for diabetic endothelial dysfunction.
Xu J, Zou MH. Xu J, et al. Circulation. 2009 Sep 29;120(13):1266-86. doi: 10.1161/CIRCULATIONAHA.108.835223. Circulation. 2009. PMID: 19786641 Free PMC article. Review. No abstract available. - Isoprostanes in Veterinary Medicine: Beyond a Biomarker.
Putman AK, Contreras GA, Sordillo LM. Putman AK, et al. Antioxidants (Basel). 2021 Jan 20;10(2):145. doi: 10.3390/antiox10020145. Antioxidants (Basel). 2021. PMID: 33498324 Free PMC article. Review. - Manganese Superoxide Dismutase Dysfunction and the Pathogenesis of Kidney Disease.
Kitada M, Xu J, Ogura Y, Monno I, Koya D. Kitada M, et al. Front Physiol. 2020 Jul 14;11:755. doi: 10.3389/fphys.2020.00755. eCollection 2020. Front Physiol. 2020. PMID: 32760286 Free PMC article. Review. - Mechanisms by which diabetes increases cardiovascular disease.
Gleissner CA, Galkina E, Nadler JL, Ley K. Gleissner CA, et al. Drug Discov Today Dis Mech. 2007;4(3):131-140. doi: 10.1016/j.ddmec.2007.12.005. Drug Discov Today Dis Mech. 2007. PMID: 18695749 Free PMC article. - Glomerular endothelial cell injury and cross talk in diabetic kidney disease.
Fu J, Lee K, Chuang PY, Liu Z, He JC. Fu J, et al. Am J Physiol Renal Physiol. 2015 Feb 15;308(4):F287-97. doi: 10.1152/ajprenal.00533.2014. Epub 2014 Nov 19. Am J Physiol Renal Physiol. 2015. PMID: 25411387 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources